Medical Device and Healthcare Industry Trends: 2026-06-03

Top 5 Headlines

• Korean Medical Device Industry: 2025 production hit 12.36 trillion KRW (up 8.1%), marking a six-year trade surplus streak led by dental implants and ultrasound devices.
• MFDS GMP Audit Rules: Regulations have tightened as the grace period for sales suspension following a delay in GMP certification renewal has been abolished, increasing the compliance burden on manufacturers.
• KOSDAQ Tier System: Medical device companies like Classys are set to benefit by entering the "Premium" tier, while biopharma firms face pressure from stricter regulations.
• FDA Deregulation: Simplified rules for low-risk AI Clinical Decision Support (CDS) software and wearable devices are creating new global expansion opportunities for Korean firms.
• Samsung at VivaTech 2026: Samsung will unveil its strategy to lead the digital health market with the theme "AI-powered connected healthcare" in Paris (June 17–20).

Key Corporate Trends

Classys — 42.7% Q1 Operating Margin and Brazil Expansion

• What's happening: Q1 revenue reached 87.2 billion KRW (up 13% YoY). The acquisition of Brazilian distributor MedSystems has strengthened its local customer base.
• Key numbers: 42.7% operating margin; operating profit dipped 4.1% due to one-time accounting factors.
• Outlook: As a likely candidate for the KOSDAQ Premium tier, the company is accelerating global diversification via South American expansion, maintaining profitability with high margins.

Samsung Electronics — AI-Powered Connected Healthcare Vision at VivaTech 2026

• What's happening: Samsung will demonstrate AI-driven connected medical experiences under the theme "Open Invitation to a Healthier Tomorrow" at VivaTech 2026 in Paris.
• Key numbers: Participation in VivaTech 2026 (approx. 500 companies expected).
• Outlook: Samsung’s ecosystem is well-aligned with the FDA’s new deregulation policies, strengthening its global digital health leadership and paving the way for AI diagnostics and remote monitoring solutions in Europe.

Korea's Medical Device Industry — 2025 Production Hits 12.36 Trillion KRW

• What's happening: Output grew 8.1% to 12.36 trillion KRW, with increased exports securing a sixth consecutive trade surplus.
• Key numbers: 12.36 trillion KRW production (+8.1%); 6-year surplus streak.
• Outlook: Driven by dental implants (e.g., Osstem Implant) and ultrasound systems, the simplified FDA process significantly boosts the global competitiveness of Korean devices for 2026.

Policy and Regulation

Abolition of Sales Suspension Grace Period for GMP Audits

• Details: The MFDS has abolished the 30-day grace period for sales suspension if GMP certification results need supplementing after expiration. Certification must be completed before expiration to continue sales.
• Impact: Manufacturers must manage renewal timelines more strictly. While this raises costs for smaller firms, large companies may find risk management easier through "Pre-consultation" programs.

KOSDAQ Tier System: Premium Tier Entry for Medical Device Firms

• Details: Under the Korea Exchange's new system, medical device giants like Classys are expected to enter the Premium tier, while small-to-mid-sized biopharma firms face stricter disclosure and monitoring.
• Impact: Increased capital-raising capabilities and investor trust for medical device firms, while biopharma may face higher costs due to regulatory pressure. Capital flow within the industry may shift toward medical devices.

Digital Health & AI Medicine

• FDA CDS Deregulation: The reduction in regulations for low-risk AI-based Clinical Decision Support software and wearables lowers market entry barriers for digital health firms, aiding the overseas expansion of Korean AI companies like Lunit and Vuno.
• Samsung Wearable AI: AI-connected care solutions debuting at VivaTech 2026 are highly compatible with the FDA’s new framework, increasing their adoption potential in European medical institutions.
• Investment Climate: Digital health startups like GiVita have successfully secured Series A funding (approx. 4.5 billion KRW), though securing insurance reimbursement remains a key challenge post-approval.

Global MedTech Context

• FDA Deregulation (Jan 2026): Easing rules for AI CDS and wearables directly accelerates the entry of Korean firms into the U.S. market, potentially shortening FDA 510(k) application timelines for AI diagnostic companies.
• Wearable Regulations: Regulatory easing for consumer wearables (Apple Watch, Oura Ring) lowers the barrier for Samsung Health and LG healthcare solutions to enter the medical-grade wearable space.
• European Tech Events: With over 500 companies attending VivaTech 2026, Korean firms are poised to showcase their technological prowess in the AI and wearable categories to the European market.

Investment, M&A, and Listing Trends

• Classys: Leveraging the MedSystems acquisition to secure the South American market; the KOSDAQ Premium tier entry will facilitate future M&A funding.
• Startups: Improved funding environment for digital health startups following recent Series A successes, though profitability hinges on achieving medical insurance reimbursement.

Insights

The convergence of a six-year trade surplus and regulatory easing by the FDA and KOSDAQ is a major boon for Korea. The FDA’s January 2026 deregulation could shave 6–12 months off U.S. market entry for AI firms like Lunit and Vuno. Simultaneously, the MFDS's strict GMP rules favor large firms like Classys and Samsung that possess robust regulatory infrastructure. Samsung's participation in VivaTech 2026 serves as a prime example of Korean companies proactively adapting to global regulatory shifts.

Weekly Checkpoints

• VivaTech 2026 (June 17-20): Watch for digital health solutions from Samsung, LG, and others, and their meetings with European medical institutions.
• MFDS Innovation Medical Device Designation: Updates on new designations and technology trends for the first half of 2026.
• KOSDAQ Tier System: Final announcement on the implementation plan, confirming Premium tier status for medical device stocks.
• FDA AI Guidelines: Monitoring for any further amendments to regulatory easing in H1 2026.

Action Items

• Manufacturers: Strengthen GMP expiration management and schedule pre-consultations to navigate stricter MFDS rules.
• Startups: Review the new FDA low-risk AI guidelines to build U.S. market entry strategies that leverage faster approval timelines.
• Investors: Monitor KOSDAQ Premium tier entry timelines for companies like Classys and watch for new M&A opportunities.